Novo Nordisk As operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Novo Nordisk As with three other
pharmaceutical manufacturers in Europe:
of UNITED KINGDOM
sales of £19.06 billion [US$24.69 billion]
of which 100%
Lonza Group AG
(5.92 billion Swiss Francs [US$6.53 billion]
of which 70%
was Pharma&Biotech), and
based in GERMANY
(16.15 billion Euros [US$19.09 billion]
of which 42%
was Life Science).
During the year ended December of 2019, sales at
Novo Nordisk As were 122.02 billion Danish Kroner (US$19.38 billion).
increase of 9.1%
versus 2018, when the company's sales were 111.83 billion Danish Kroner.
Sales of Diabetes and Obesity saw an increase
9.5% in 2019, from
93.90 billion Danish Kroner to 102.84 billion Danish Kroner.